Blog
The case for patient-controlled rare disease data across science, policy, and the lived experience.
Featured
Vision
It is no longer good business to leave rare diseases behind
The math changed. The institutions that retool first capture leadership.
Read →This week
Regulatory
Our FDA Comment: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program
Cureledger's May 27, 2026 comment to Docket FDA-2026-N-4390: rare disease as the pilot's most generalizable use case, within-person variability as the decision-quality threshold, privacy for cohorts under 100, and data custody that outlives the sponsor.
Read →Data Sovereignty
Preventing AI medicine's biggest trap for rare disease
Why AI drug discovery becomes extraction without ownership infrastructure.
Read →
Vision
The rare disease singularity
Four capabilities converged. Cures are reachable.
Read →